Abstract 1689TiP
Background
One of the unmet needs in Lung Cancer Care is the Stigma of patients due to the smoking habits; the condition of current smoker or former smoker causes the perception of the one’s incorrect lifestyle so, more than in other pathologies, patients with lung cancer are burdened with feelings of guilt and self-devaluation in anticipation of a negative social judgment. In addition to detecting this phenomenon, the study aims to psychologically support lung cancer patients, as well as smokers who belong to the Antismoking Centre in our Institute and who present with high levels of distress, through a psychotherapeutic path according to the EMDR (Eye Movement Desensitization and Reprocessing) model which could allow the reworking of traumatic or emotionally stressful moments, linked to the phases of the disease and to the personal history. The EMDR is one of the techniques that support smokers in quitting; the processing of the experience that occurs with EMDR allows the subject, through desensitization and cognitive restructuring, to change perspective and adopt more appropriate behaviors.
Trial design
Objectives of this study are the following: 1) to document the presence of stigma in current smokers or former smokers with lung cancer and subjects who undertake a smoke cessation program ; 2) to measure the correlation between stigma, level of anxiety, depression, quality of life and psychophysical well-being in the different phases of the disease starting from diagnosis and throughout treatment process;3) to investigate the impact and the efficacy of the EMDR model through the psychological re-evaluation of stress, depression and anxiety. The sociocultural, psychological factors and lifestyles of the participants will be investigated, including any gender-related differences regarding the Lung Cancer stigma, smoking habits and the outcome of a tobacco cessation process. A number of 45 subjects is planned to be recruited.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1709P - Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Presenter: Deepak Kilari
Session: Poster session 11
1710P - Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Presenter: Benoit Blanchet
Session: Poster session 11
1711P - Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Presenter: John McGrane
Session: Poster session 11
1712P - Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Presenter: Jwa Hoon Kim
Session: Poster session 11
1713P - A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Presenter: Jue Hou
Session: Poster session 11
1714P - Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Presenter: Simon Garinet
Session: Poster session 11
1715P - Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma
Presenter: Xu Zhang
Session: Poster session 11
1716P - Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Presenter: martina catalano
Session: Poster session 11